ArticleAbdominal radiology (New York)2026
Prognostic imaging features of ovarian clear cell carcinoma on multiparametric MRI.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo compare preoperative MRI features between ovarian clear cell carcinoma (CCC) patients with favorable versus unfavorable clinical outcomes and to identify imaging predictors associated with adverse outcomes.
methodsWe retrospectively analyzed patients with pathologically confirmed CCC to compare preoperative MRI and clinical features between the recurrence-free and unfavorable-outcome groups. Quantitative variables included MRI parameters such as tumor size, T1 ratio of the cystic component, and for the solid component, maximum width and height, T2 ratio, apparent diffusion coefficient (ADC), and dynamic contrast-enhanced (DCE) metrics, as well as clinical/laboratory data (age and serum tumor marker levels). Qualitative variables included MRI findings such as number of locules, number of solid components (≤ 3 vs. ≥4 solid components or diffuse mural thickening), presence of marked T2 hyperintensity, growth pattern, presence of necrosis, and time-intensity curve (TIC) pattern, as well as FIGO stage, and surgical completeness.
resultsSeventy-two patients were included (recurrence-free, n = 45; unfavorable-outcome, n = 27). The distribution of FIGO stage differed between the groups (p < 0.001), and complete surgery was achieved significantly less often in the unfavorable-outcome group (77.8%, p = 0.002). Among the MRI parameters, only ≥ 4 solid components were significantly associated with unfavorable outcomes (p = 0.020). In stage I-II cases, the same trend was observed, although not significant (p = 0.147). No significant associations were observed for any other variables, including tumor size, T1 ratio of the cystic component, maximum width and height of the solid component, growth pattern, T2 ratio, ADC, DCE metrics, TIC pattern, or clinical and laboratory data (p = 0.050-1.000).
conclusionIn this cohort of CCC patients, multiparametric MRI showed that the presence of four or more solid components, together with FIGO stage and surgical completeness, was associated with unfavorable clinical outcomes, suggesting a potential role for MRI-based risk stratification that warrants external validation.
Indexed as
Identifiers
41171408What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.